Libourne – 26 September 2018 – Fermentalg (Euronext – FALG), a French market leader in microalgae for human nutrition and health, and ADL BioPharma (ADL Bionatur group, Madrid – ADL), a major European player for the development and production of fermentation process-based projects, today announce the conclusion of a long-term manufacturing contrat to produce Fermentalg's algal oil DHA ORIGINS ®.
ADL BioPharma, 100% subsidiary of ADL Bionatur group, is the European leader in biotech contract manufacturing fermentation industry. The company owns and operates one of the most advanced industrial biotechnology plant in Southern Europe with a current fermentation capacity of 2,400 m3. Combined with its large scale of operations and experience in the field, ADL Biopharma offers the highest quality standards, including European and US FDA certifications for the pharmaceutical, cosmetics and food industries.
ADL BioPharma and Fermentalg plan to complete the validation and technology transfer phase before the end of 2018, following which ADL will dedicate a part of its fermentation capacity to Fermentalg productions, allowing it to supply hundreds of tons to the growing DHA ORIGINS 550® market.
Philippe Lavielle, CEO of Fermentalg, says: “This long term contract, following the signature of a major commercial partnership, secures our supply of our high value DHA ORIGINS ® 550®, the algal DHA with the highest natural concentration on the market. ADL Biopharma's scale, extensive experience and capabilities in fermentation and extraction technologies will support our commitment to become one of the world's largest producer of algal DHA.”
Pilar de la Huerta, CEO of ADL BioPharma, says: “This is the fourth long term CMO contract that we signed during the latest ten months, guaranteeing more than 85% of our current business plan for the next years. This is a validation of our assumptions about the market needs for state of the art fermentation industrial sites. We are very proud of the quality of our customers in terms of innovation and quality. Fermentalg is doing a great development with their product, targeting the premium algal Omega-3 market worldwide for human nutrition, and we are happy to be their partner for a key part of their value chain.”
An expert in research and bio-industrial use of microalgae, Fermentalg seeks to provide sustainable solutions and innovative products that contribute towards the creation of natural, healthy and effective products. Our business: development, production and sale of active ingredients extracted from microalgae for the agri-food, health and nutrition sectors. Natural nutritional oils, pigments and antioxidants, as well as specialty proteins, comprise our present and future offering.
Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG).
For more information, visit: www.fermentalg.com
|Contact - Journalists:||Contact - Investors:|
|ACTUS finance & communication
Tel: +33 (0)1 53 67 36 90
|ACTUS finance & communication
Tel: +33 (0)1 53 67 36 78
About ADL BioPharma:
ADL Bionatur Solutions, controlled by the investment fund Black Toro Capital (BTC) with 73% of the capital, is the company resulting from the integration between ADL Biopharma and Bionaturis. Integration involved combining in a single entity the specialization in R & D in health products and services, with industrial production by fermentation and manufacturing capacity. ADL Bionatur Solutions is listed on the Spanish Alternative Market MaB (Ticker ADL) since May 2018. The company provides qualified employment to more than 250 people and its markets are mainly located in Europe and the United States. ADL Biopharma is part of ADL Bionatur Solutions, a European leader in biotech health sector focused on high value fermentation products. For more information, visit: www.adlbionatur.com
Contact details (journalists and investors)
MC Services AG
Dr. Claudia Gutjahr-Löse